Onkologie. 2023:17(2):119-122 | DOI: 10.36290/xon.2023.024

Types and characteristics of renal lesions - diagnosis, treatment and prognosis

Vít Paldus1, Vladimír Šámal1, 2, Marie Pechová1, Igor Richter3
1 Urologické oddělení, Krajská nemocnice Liberec, a. s.
2 Urologická klinika, LF a FN Hradec Králové
3 Komplexní onkologické centrum, Krajská nemocnice Liberec, a. s.

Characteristics of renal lesions may predict further development of the disease, its prognosis and thus becomes part of the decision-making process, as to which treatment strategy to choose, right from the beginning. Unfortunately, a simple TMN classification of the disease stage may not always be sufficient. Some of the centrally localized renal cell carcinomas (RCC) may be re-evaluated from the primary stage cT1 to the final pathological stage pT3a. Cystic renal lesions represent another specific group in the evaluation of RCC. Their diagnostic work up and treatment strategy is guided by the Bosniak classification based on the CT. The clinical approach towards the cysts of IIF and III categories may be difficult at least in some cases. According to the available data up to 3-10% of the Bosniak category IIF complex renal cysts may be malignant, while up to 49% of the category III cysts may be benign. In general, the prognosis of cystic tumors is better than that of the solid tumors.

Keywords: renal cell carcinoma, renal cystic lesion, Bosniak classification, prognosis.

Accepted: April 26, 2023; Published: April 27, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Paldus V, Šámal V, Pechová M, Richter I. Types and characteristics of renal lesions - diagnosis, treatment and prognosis. Onkologie. 2023;17(2):119-122. doi: 10.36290/xon.2023.024.
Download citation

References

  1. Lee CT, Katz J, Shi W, et al. Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol. 2000;163(3):730-736. Go to original source... Go to PubMed...
  2. Ljungberg, B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol. 2019;75(5):799-810. Go to original source... Go to PubMed...
  3. Bosniak MA. Problems in the radiologic diagnosis of renal parenchymal tumors. Urol Clin North Am. 1993;20(2):217-230. Go to original source... Go to PubMed...
  4. Israel GM, Bosniak MA. MR imaging of cystic renal masses. Magn Reson Imaging Clin N Am. 2004;12(3):403-412. Go to original source... Go to PubMed...
  5. Wood CG, Stromberg LJ, Harmath CB, et al. CT and MR imaging for evaluation of cystic renal lesions and diseases. Radiographics. 2015;35(1):125-141. Go to original source... Go to PubMed...
  6. Israel GM, Hindman N, Bosniak MA. Evaluation of cystic renal masses: comparison of CT and MR imaging by using the Bosniak classification system. Radiology. 2004;231(2):365-371. Go to original source... Go to PubMed...
  7. Silverman SG, Pedrosa I, Ellis JH, et al. Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment. Radiology. 2019; 292:475. Go to original source... Go to PubMed...
  8. Defortescu G, Cornu JN, Béjar S, et al. Diagnostic performance of contrast-enhanced ultrasonography and magnetic resonance imaging for the assessment of complex renal cysts: A prospective study. Int J Urol. 2017;24:184. Go to original source... Go to PubMed...
  9. Graumann O, Osther SS, Karstoft J, et al. Bosniak classification system: a prospective comparison of CT, contrast-enhanced US, and MR for categorizing complex renal cystic masses. Acta Radiol. 2015. Go to original source...
  10. Ascenti G, Mazziotti S, Zimbaro G, et al. Complex cystic renal masses: characterization with contrast enhanced US. Radiology. 2007;243(1):158-165. Go to original source... Go to PubMed...
  11. Foukal J, Mechl M, Janoušová E. Srovnání kontrastní ultrasonografie a CT v klasifikaci cystických lézí ledvin. In: Mechl M. Česká radiologie. Praha: Grada; 2014:30-39.
  12. Furrer MA, Spycher SC, Büttiker SM, et al. Comparison of the Diagnostic Performance of Contrast-enhanced Ultrasound with That of Contrast-enhanced Computed Tomography and Contrast-enhanced Magnetic Resonance Imaging in the Evaluation of Renal Masses: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2020;3:464. Go to original source... Go to PubMed...
  13. Ellimoottil C, Greco KA, Hart S, et al. New modalities for evaluation and surveillance of complex renal cysts. J Urol. 2014;192(6):1604-1611. Go to original source... Go to PubMed...
  14. Richard PO, Jewett MA, Bhatt JR, et al. Renal Tumor Biopsy for Small Renal Masses: A Single-center 13-year. Experience. Eur Urol. 2015;68:1007. Go to original source... Go to PubMed...
  15. Volpe A, Mattar K, Finelli A, et al. Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. J Urol. 2008;180:2333. Go to original source... Go to PubMed...
  16. Marconi L, Debestani S, Lam TB, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol. 2016;69:660. Go to original source... Go to PubMed...
  17. Mucci LA, Jacob BH, Jennifer JH, et al. Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. JAMA. 2016;315:68. Go to original source... Go to PubMed...
  18. Shuch B, Srinivas V, Christopher JR, et al. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol, 2014;32:431. Go to original source... Go to PubMed...
  19. Lane BR, Abouassaly R, Gao T, et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer. 2010;116:3119. Go to original source... Go to PubMed...
  20. Hollingsworth JM, Miller DC, Daignault S, et al. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007;109:1763. Go to original source... Go to PubMed...
  21. Pierorazio PM, Johnson MH, Ball MW, et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol. 2015;68:408. Go to original source... Go to PubMed...
  22. Uzosike AC, Patel HD, Alam R, et al. Growth Kinetics of Small Renal Masses on Active Surveillance: Variability and Results from the DISSRM Registry. J Urol. 2018;199:641. Go to original source... Go to PubMed...
  23. Park HS, Lee K, Moon KC. Determination of the cutoff value of the proportion of cystic change for prognostic stratification of clear cell renal cell carcinoma. J Urol. 2011;186(2): 423-429. Go to original source... Go to PubMed...
  24. Corica FA, Iczkowski KA, Cheng L, et al. Cystic renal cell carcinoma is cured by resection: a study of 24 cases with long-term followup. J Urol. 1999;161(2):408-411. Go to original source... Go to PubMed...
  25. Huber J, Winkler A, Jakobi H, et al. Preoperative decision making for renal cell carcinoma: cystic morphology in cross-sectional imaging might predict lower malignant potential. Urol Oncol. 2014;32(1):37.e1-6. Go to original source... Go to PubMed...
  26. Silverman SG, Israel GM, Herts BR, et al. Management of the incidental renal mass. Radiology. 2008;249(1):16-31. Go to original source... Go to PubMed...
  27. Bosniak MA. The current radiological approach to renal cysts. Radiology. 1986;158(1):1-10. Go to original source... Go to PubMed...
  28. Berland LL, Silverman SG, Gore RM, et al. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol. 2010;7(10):754-773. Go to original source... Go to PubMed...
  29. O'Malley RL, Godoy G, Hecht EM, et al. Bosniak category IIF designation and surgery for complex renal cysts. J Urol. 2009;182:1091-1095. PMID:19616809.Další literatura u autora a na www.onkologiecs.cz Go to original source... Go to PubMed...
  30. Smith AD, Remer EM, Cox KL, et al. Bosniak category IIF and III cystic renal lesions: outcomes and associations. Radiology. 2012;262:152-160. PMID:22106359. Go to original source... Go to PubMed...
  31. Graumann SS, Osther J, Karstoft J, et al. Evaluation of Bosniak category IIF complex renal cysts. Insights Imaging. 2013;4:471-480. PMID:23673454. Go to original source... Go to PubMed...
  32. El-Mokadem I, Budak M, Pillai S, et al. Progression, interobserver agreement, and malignancy rate in complex renal cysts (Bosniak category IIF). Urol Oncol. 2014;32:24:e21-27. PMID:23395236. Go to original source... Go to PubMed...
  33. Schoots IG, Zaccai K, Hunink MG, et al. Bosniak Classification for Complex Renal Cysts Reevaluated: A Systematic Review. J Urol. 2017;198:12. Go to original source... Go to PubMed...
  34. McGuire BB, Fitzpatrick JM. The diagnosis and management of complex renal cysts. Curr Opin Urol. 2010;20(5):349-354. Go to original source... Go to PubMed...
  35. Pitra T, Pivovarčíková K, Tupý R, et al. Cystické léze ledvin: zkušenosti jednoho urologického centra. Ces Urol. 2019;23(2):131-139. Go to original source...
  36. Donin NM, Mohan S, Pham H, et al. Clinicopathologic outcomes of cystic renal cell carcinoma. Clin Genitourin Cancer. 2015;13:67. Go to original source... Go to PubMed...
  37. Park JJ, Jeong BC, Kim CK, et al. Postoperative Outcome of Cystic Renal Cell Carcinoma Defined on Preoperative Imaging: A Retrospective Study. J Urol. 2017;197:991. Go to original source... Go to PubMed...
  38. Chandrasekar T, Ahmad AE, Faddak K, et al. Natural History of Complex Renal Cysts: Clinical Evidence Supporting Active Surveillance. J Urol. 2018;199:633. Go to original source... Go to PubMed...
  39. Nouhaud FX, Bernhard JCH, Bigot P, et al. Contemporary assessment of the correlation between Bosniak classification and histological characteristics of surgically removed atypical renal cysts (UroCCR-12 study). World J Urol. 2018;36:1643. Go to original source... Go to PubMed...
  40. Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913-924. Go to original source... Go to PubMed...
  41. Gong K, Zhang N, He Z, et al. Multilocular cystic renal cell carcinoma: an experience of clinical management for 31 cases. J Cancer Res Clin Oncol. 2008;134(4):433-437. Go to original source... Go to PubMed...
  42. Kuroda N, Ohe C, Mikami S, et al. Multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol. 2012;27(8):969-974. Go to PubMed...
  43. You D, Shim M, Jeong IG, et al. Multilocular cystic renal cell carcinoma: clinicopathological features and preoperative prediction using multiphase computed tomography. BJU Int. 2011;108(9):1444-1449. Go to original source... Go to PubMed...
  44. Shah PH, Moreira DM, Patel VR, et al. Partial Nephrectomy is Associated with Higher Risk of Relapse Compared with Radical Nephrectomy for Clinical Stage T1 Renal Cell Carcinoma Pathologically Up Staged to T3a.J Urol. 2017;198:289. Go to original source... Go to PubMed...
  45. Patel SH, Uzzo RG, Larcher A, et al. Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis. Clin Genitourin Cancer. 2020;18:e723. Go to original source... Go to PubMed...
  46. Mir MC, Derweesh I, Porpiglia F, et al. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol. 2017;71:606. Go to original source... Go to PubMed...
  47. Janssen MWW, Linxweiler J, Terwey S, et al. Survival outcomes in patients with large (>/=7 cm) clear cell renal cell carcinomas treated with nephron-sparing surgery versus radical nephrectomy: Results of a multicenter cohort with long-term follow-up. PLoS One. 2018;13:e0196427. Go to original source... Go to PubMed...
  48. Chang KD, Raheem AA, Kim KH, et al. Functional and oncological outcomes of open, laparoscopic and robot-assisted partial nephrectomy: a multicentre comparative matched-pair analyses with a median of 5 years' follow-up. BJU Int. 2018;122:618. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.